Introduction {#Sec1}
============

Polycaprolactone (PCL)-1 dermal filler (Ellansé™; AQTIS Medical, Utrecht, the Netherlands) is a soft tissue dermal filler based on PCL microspheres. The smooth and totally spherical-shaped PCL microspheres (25--50 μm) are homogenously suspended in a tailor-made aqueous carboxymethylcellulose (CMC) gel carrier.

PCL and CMC individually have an excellent and established biocompatibility profile and have been used successfully in numerous Conformité Européenne marked and US Food and Drug Administration approved medical devices, such as dermal fillers, oral and maxillofacial surgery, wound dressing and controlled drug delivery \[[@CR1]--[@CR6]\].

PCL is a totally bioresorbable, nontoxic medical polymer and is attractive for use in medical devices because of its controlled and safe bioresorption process \[[@CR7]--[@CR11]\]. With ^3^H-labeled PCL and C^14^-labeled PCL implantation studies, it has been proved that PCL was completely excreted from the body \[[@CR7], [@CR8]\].

After treatment the CMC gel carrier is gradually resorbed by macrophages over a period of several weeks, during which the PCL microspheres will trigger a natural response of the human skin and stimulate a natural wound-healing process through neocollagenesis. The new collagen replaces the volume of the resorbed carrier. The microspheres are not phagocytosed because of their size and surface characteristics. The PCL microspheres are totally smooth and spherical shaped, which has been shown to be optimal for dermal fillers \[[@CR12], [@CR13]\]. The PCL dermal filler is indicated for deep dermal and subdermal implantation.

In 2007 Busso and Applebaum \[[@CR14]\] published a report of their experiences in mixing a calcium hydroxylapatite-based dermal filler with lidocaine for use of the soft tissue filler in treatment of the hand. The result of mixing the two components is that the treatment is less painful to the patient than the conventional hand injection, and is characterized by less swelling and bruising, with minimal posttreatment downtime.

Increasing numbers of physicians are adopting and using this technique for mixing the PCL dermal filler with standard 2.0% lidocaine-hydrochloride (HCl) solutions, up to 0.19 mL of lidocaine with a 1.1 mL syringe of PCL dermal filler. Mixing 0.19 mL of 2.0% lidocaine solution with 1.1 mL of PCL dermal filler yields a 0.3% lidocaine concentration. This concentration is equivalent to that found in other soft tissue fillers, such as Restylane and Juvederm \[[@CR15], [@CR16]\]. The authors suggest that adding up to 0.3% of the anesthetic agent lidocaine to the PCL-based filler will not substantially affect its characteristics, confirming the usability of this mixture in clinical practice.

Materials and Methods {#Sec2}
=====================

Study Purpose and Design {#Sec3}
------------------------

In this study the characterization of the physical properties of PCL dermal filler mixed with plain 2.0% lidocaine-HCl solutions and combined 2.0% lidocaine-HCl and epinephrine under various mixing condition is investigated.

A range of lidocaine and lidocaine with epinephrine concentrations was mixed with the PLC dermal filler to evaluate the changes in dynamic viscosity and elasticity, extrusion force, pH, and needle jam rates. Investigators also evaluated the mixtures at the front, middle, and back of each mixed syringe as a measure of mixing efficiency.

Materials and Equipment {#Sec4}
-----------------------

For this study 1.1 mL syringes of the PCL-1 dermal filler were used. The usage of the PCL dermal filler in this study is representative of the entire product line as all the relevant product characteristics are identical throughout the entire product range. Testing was performed on three different commercial lots.

The 2.0% lidocaine solution was composed of anhydrous lidocaine-HCl (20 mg/mL) (Xylocaine 2.0%; Astra Zeneca BV, Zoetermeer, the Netherlands). The 2.0% lidocaine solution with epinephrine was composed of anhydrous lidocaine-HCl (20 mg/mL), epinephrine (5 μg/mL) (Xylocaine 2.0% with epinephrine; Astra Zeneca BV).

A rheometer (Haake RS-6000; Thermo Electron GmbH, Karlsruhe, Germany) was used to measure the dynamic viscosity and elasticity of the media. Rheology was evaluated with a titanium rotor, with a gap of 0.105 mm and tau (τ) of 5 Pa, over a frequency sweep of 0.1--10 Hz evaluated at 0.6 Hz. Extrusion force was measured by a material tester (model H1Ks; Tinius Olsen, Ltd., Salfords, Surrey, UK). Extrusion force was evaluated through a 27G¾ inch needle with an extension rate of 1 mL/min.

Media pH was measured using a pH meter with a probe (pH340I, and Sentix 41 probe, respectively; WTW, Weilheim, Germany). The pH was obtained by completely coating the glass bulb of the pH probe with media. The female-to-female Luer lock connectors used to connect the mixing and media syringes were from Baxa (rapid fill connector, ref. 13901; Bracknell, Berkshire, UK).

Procedures {#Sec5}
----------

For the PCL-1 dermal filler, 1.1 mL syringes were mixed with one of four volumes of 2.0% lidocaine or 2.0% lidocaine with epinephrine solution: 0.05 mL (0.09% final lidocaine-HCl); 0.10 mL (0.17% final lidocaine-HCl); 0.14 mL (0.23% final lidocaine-HCl); 0.19 mL (0.30% final lidocaine-HCl).

One milliliter mixing syringes (Beckton Dickinson, Franklin Lakes, New Jersey, USA) were used to withdraw the lidocaine solution from the 20 mL vial via a 21G$\documentclass[12pt]{minimal}
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                \begin{document}$$ {\raise0.5ex\hbox{$\scriptstyle 5$} \kern-0.1em/\kern-0.15em \lower0.25ex\hbox{$\scriptstyle 8$}} $$\end{document}$ inch needle. The push rod of the mixing syringe was drawn back to make sure all the lidocaine solution was cleared from the needle and afterwards depressed to remove all excess air. Next, the mixing syringe with lidocaine was firmly connected to a syringe of PCL dermal filler using a female-to-female Luer lock connector (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Polycaprolactone-based dermal filler mixed with lidocaine, using a female-to-female Luer lock connector

Lidocaine and PCL dermal filler were mixed by alternately depressing the plungers on the mixing and media syringes. Each mixing stroke was composed of one complete compression of the dermal filler syringe push rod, followed by one complete compression of the mixing syringe push rod. Push rods were compressed firmly and quickly, at approximately two compressions per second.

Following mixing, the mixing syringe and Luer lock connector were removed and discarded, and the lidocaine/dermal filler mixture was recapped with the original media syringe cap. The dermal filler-lidocaine blends were tested between 15 min and 120 min after mixing with lidocaine.

Results {#Sec6}
=======

Number of Passes Between Syringes Sufficient for Blending of Lidocaine with PCL Dermal Filler {#Sec7}
---------------------------------------------------------------------------------------------

The extrusion force was used to determine the number of passes between syringes needed for sufficient blending of lidocaine with the PCL dermal filler. With adequate mixing of the components the difference in viscosity across all regions of the syringe is minimal and the extrusion force profile is uniform from the front to the back of the syringe.

The difference in viscosity from the front to the back increased with increasing volume of lidocaine, suggesting that larger volumes of lidocaine required more mixing than small volumes. It also reflects a greater magnitude of change in physical properties with increasing concentration of lidocaine.

Figure [2](#Fig2){ref-type="fig"} shows the extrusion force of PCL dermal filler without lidocaine and zero mixing strokes, demonstrating a uniform profile from the front to the back.Fig. 2Extrusion force profile of polycaprolactone dermal filler without lidocaine, 0 mixing strokes

Five mixing passes did not provide adequate mixing for any volume tested. The extrusion force profile of PCL dermal filler mixed with 0.19 mL lidocaine with five mixing strokes can be seen in Fig. [3](#Fig3){ref-type="fig"}, showing an increase in extrusion force from the front to the back of the syringe.Fig. 3Extrusion force profile of polycaprolactone dermal filler mixed with 0.19 mL lidocaine using a female-to-female Luer lock connector, five mixing strokes

Ten mixing passes provided adequate mixing for 0.05 mL of lidocaine, but not for the other volumes. The extrusion force profile of PCL dermal filler mixed with 0.19 mL lidocaine with 10 mixing strokes, shown in Fig. [4](#Fig4){ref-type="fig"}, demonstrates a nonuniform extrusion profile reflecting the front-to-back inhomogeneity.Fig. 4Extrusion force profile of polycaprolactone dermal filler mixed with 0.19 mL lidocaine using a female-to-female Luer lock connector, 10 mixing strokes

Following 15 mixing strokes, the extrusion force was uniform from the front to the back of the syringe for all lidocaine volumes tested, even at the maximum tested volume of lidocaine. Figure [5](#Fig5){ref-type="fig"} shows the uniform extrusion profile of PCL dermal filler mixed with 0.19 mL lidocaine with 15 mixing strokes.Fig. 5Extrusion force profile of polycaprolactone dermal filler mixed with 0.19 mL lidocaine using a female-to-female Luer lock connector, 15 mixing strokes

Dynamic Viscosity of PCL Dermal Filler Compared to PCL Dermal Filler with Lidocaine Mixtures with or without Epinephrine {#Sec8}
------------------------------------------------------------------------------------------------------------------------

The dynamic viscosity measures the way a fluid responds to stresses and strains. The dynamic viscosity of the PCL dermal filler decreased with increasing lidocaine concentration without or with epinephrine. Figure [6](#Fig6){ref-type="fig"} shows the dynamic viscosity procentual difference of PCL dermal filler blended with 0.05 mL, 0.10 mL, 0.14 mL, and 0.19 mL 2.0% lidocaine solution mixed with 15 mixing strokes. No statistically significant viscosity differences were measured for lidocaine solutions with or without epinephrine.Fig. 6Dynamic viscosity procentual difference of polycaprolactone dermal filler mixed with various volumes of 2.0% lidocaine with and without epinephrine (15 mixing strokes, 0.6 Hz)

Even at 0.23 mL of lidocaine solution blended with the PCL dermal filler, the CMC gel viscosity/elasticity was sufficient enough to keep the PCL microspheres in suspension in time (not shown).

Extrusion Forces of PCL Dermal Filler Compared to PCL Dermal Filler with Lidocaine {#Sec9}
----------------------------------------------------------------------------------

The extrusion forces of the PCL dermal filler mixed with lidocaine were lower than those of the PCL dermal filler alone. The average extrusion force decreased with the increase in volume of lidocaine added to the 1.1 mL PCL dermal filler syringe.

In Fig. [7](#Fig7){ref-type="fig"} the average extrusion forces of PCL dermal without lidocaine and PCL dermal filler blended with 0.05 mL, 0.10 mL, 0.14 mL, and 0.19 mL 2.0% lidocaine solution mixed with 15 mixing strokes are shown. The average extrusion force of PCL dermal filler without lidocaine through a 27G¾ inch needle was 17.2 N and decreases to 13.0 N for PCL dermal filler mixed with 0.19 mL 2.0% lidocaine solution.Fig. 7Average extrusion force of polycaprolactone dermal filler mixed with various volumes of 2.0% lidocaine (15 mixing strokes)

Differences in average extrusion force for PCL dermal filler mixed with lidocaine with and without epinephrine was not statistically significant for all volumes, suggesting that epinephrine had no effect on the extrusion force.

Incidence of Needle Jamming in PCL Dermal Filler Blended with Lidocaine with or without Epinephrine {#Sec10}
---------------------------------------------------------------------------------------------------

Needle jamming may occur if there is a cluster of PCL microspheres in the CMC gel carrier.

No needle jams were observed in any of the extrusion tests, indicating optimal homogeneity and suspension of the PCL microspheres in the CMC gel carrier after mixing with lidocaine with or without epinephrine.

Elasticity and pH of PCL Dermal Filler Blended with Lidocaine Compared to PCL Dermal Filler without Lidocaine {#Sec11}
-------------------------------------------------------------------------------------------------------------

The tan delta (δ) values (the tangent of the ratio loss modulus \[G′\] over the storage modulus \[G″\]) provides a quantitative tool to evaluate the relative elasticity of the media. The elasticity of PCL dermal filler decreased with increasing concentrations of lidocaine solution. Figure [8](#Fig8){ref-type="fig"} shows the elasticity percentage difference of PCL dermal filler blended with various volumes of 2.0% lidocaine with and without epinephrine mixed with 15 strokes. The PCL dermal filler blends were less elastic than PCL dermal filler without lidocaine solution. No statistically significant elasticity differences were measured for lidocaine solutions with or without epinephrine.Fig. 8Elasticity of PCL dermal filler mixed with various volumes of 2.0% lidocaine with and without epinephrine (15 mixing strokes)

The pH was between 7.1 and 7.2 for all tested samples.

Discussion {#Sec12}
==========

Hand mixing lidocaine or lidocaine with epinephrine with the PCL dermal filler causes no significant changes to the physical properties of the original formulation. With 15 back-and-forth passes the anesthetic agent(s) can adequately be mixed into the gel resulting in a homogenous blend. The viscosity/elasticity of the gel in the PCL dermal filler mixed with 2.0% lidocaine with or without epinephrine is sufficient to keep the PCL microspheres in suspension even after 24 h. There were no needle jams, indicating that the PCL microspheres were homogenously suspended in the gel, even after mixing the dermal filler with the anesthetic agent. The pH values of the PCL dermal filler mixed with lidocaine with or without epinephrine are equivalent to those of the original dermal filler. The viscosity, elasticity, and the extrusion force of the dermal filler decrease with increasing lidocaine content. There was no statistically significant change in physical properties for lidocaine solutions with or without epinephrine. The changes in physical properties are identical for the entire product range.

Mixing a lidocaine solution with the dermal filler obviates the need for nerve blocks or local infiltration, thereby reducing the treatment times and prevents tissue distortion that may be caused by injecting local anesthetics. This may also positively affect the patients' treatment experience and satisfaction. In addition, previous studies have shown that the addition of lidocaine to collagen-based dermal fillers resulted in less swelling and bruising \[[@CR17]\], potentially due to the antihistaminergic effect of lidocaine on mast cells \[[@CR18]\]. Similar findings have been reported for hyaluronic acid-based dermal fillers mixed with lidocaine, also showing a reduction in swelling, erythema, and bruising \[[@CR16], [@CR19]--[@CR21]\]. As lidocaine is suggested to decrease these side effects, this is also expected for the PCL-based dermal filler mixed with lidocaine.

The limitations of this study are that it does not investigate the influence of lidocaine and epinephrine on the clinical safety and performance of the PCL dermal filler, and the influence of the clinical anesthetic effect of lidocaine after mixing with the PCL dermal filler.

This study does not address a potential interaction of lidocaine or epinephrine with the components of the PCL dermal filler and its potential influence on anesthetic efficacy. It is expected that, because of its hydrophilicity, lidocaine will be situated in the aqueous (hydrophilic) CMC gel carrier. Predicted on the hydrophobicity of the nonporous PCL microspheres \[[@CR22]\] no affinity is expected between lidocaine and PCL microspheres, and there will be no driving force of the lidocaine to migrate into the PCL microspheres.

This is supported by a study describing the release profile of lidocaine from PCL threads \[[@CR23]\]. PCL pellets were compounded with lidocaine and then extruded to obtain highly loaded threads. The lidocaine release profile showed a rapid release in the first hours and completed in a few days, indicating that there is no affinity or reaction between the PCL matrix and lidocaine.

It is not expected that lidocaine will bind or react with the CMC carrier, but is free to move and yield the desired anesthetic effect. CMC is a known time-release agent for lidocaine \[[@CR24]\], and there are several commercial medical products available based on CMC gel and lidocaine as an anesthetic agent.

This study does not address the effect of the premixed anesthetic on the clinical efficacy of the PCL dermal filler. Physicians have reported no decrease in clinical efficacy after mixing the PCL dermal filler with lidocaine with or without epinephrine, as has also been reported for hyaluronic acid-based dermal fillers containing lidocaine (for review, see Smith and Cockerham \[[@CR21]\]). Planned (pre)clinical studies with lidocaine premixed before treatment and lidocaine incorporated in the PCL dermal filler syringe itself are aimed at confirming this.

Conclusion {#Sec13}
==========

The advantages of mixing lidocaine with PCL dermal filler before treatment are lower viscosity and elasticity, lower extrusion force, providing a greater ease of molding, increased patient comfort, reduced need for nerve blocks and infiltration anesthesia, which may be attractive for both physicians and patients.
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